预约演示
更新于：2025-10-30
Dexmedetomidine Hydrochloride
盐酸右美托咪定
更新于：2025-10-30
概要
基本信息
原研机构 |
最高研发阶段批准上市 |
首次获批日期 美国 (1999-12-17), |
最高研发阶段(中国)批准上市 |
特殊审评突破性疗法 (美国)、快速通道 (美国)、优先审评 (中国) |
登录后查看时间轴
结构/序列
分子式C13H17ClN2 |
InChIKeyVPNGEIHDPSLNMU-MERQFXBCSA-N |
CAS号145108-58-3 |
关联
5,212
项与 盐酸右美托咪定 相关的临床试验CTRI/2024/10/075414
Efficacy of external oblique intercostal block (EOIB) with or without dexmedetomidine on postoperative anaglesia in laparoscopic upper abdominal surgeries – a double blinded randomised control trial - Nil
ChiCTR2500109841
The mechanism study of dexmedetomidine improving epidural anesthesia-related parturient fever through mitochondrial autophagy pathway based on the regulation of FUNDC1 by ALKBH5-mediated m6A modification
NCT05619627
Utility of Oral Dexmedetomidine as the Sole Sedative Agent in Pediatric Population Undergoing MRI
100 项与 盐酸右美托咪定 相关的临床结果
登录后查看更多信息
100 项与 盐酸右美托咪定 相关的转化医学
登录后查看更多信息
100 项与 盐酸右美托咪定 相关的专利（医药）
登录后查看更多信息
14,111
项与 盐酸右美托咪定 相关的文献（医药）2026-02-01JOURNAL OF CRITICAL CARE
The effect of dexmedetomidine on clinical and management outcomes in patients with septic shock: A systematic review and meta-analysis of randomized trials
Article
作者: Patel, Bela ; Saab, Omar ; Koenig, Michael ; Alsagban, Alhareth ; Al-Obaidi, Hasan ; Algodi, Marwah
BACKGROUND:
Septic shock constitutes a significant health concern, resulting in substantial morbidity and mortality. Dexmedetomidine (DEX) was reported to significantly mitigate vasopressor resistance in septic shock, enhancing clinical outcomes. We aim to investigate DEX effect on mortality, clinical, and management outcomes in septic shock patients.
METHODS:
Systematic review and meta-analysis synthesizing evidence from randomized controlled trials (RCTs) obtained from PubMed, CENTRAL, Scopus, and Web of Science until January 2025 without language restrictions. Using Stata MP v. 17, fixed-effects model used to report dichotomous outcomes and continuous outcomes using relative risk (RR) and mean difference (MD), respectively, with a 95 % confidence interval (CI).
PROSPERO ID:
CRD42025641437.
RESULTS:
Eight RCTs and 662 patients were included. There was no significant difference between DEX and usual care for the primary outcome of in-hospital mortality (RR: 0.78, 95 % CI [0.56, 1.11], p = 0.17). Similarly, no significant differences were found for secondary outcomes of ICU mortality (RR: 0.73, 95 % CI [0.48, 1.13], p = 0.16), and long-term mortality (RR: 0.90, 95 % CI [0.73, 1.11], p = 0.33). No significant difference between both groups regarding the ICU length of stay (LOS) (MD: 0.07, 95 % CI [-0.97, 1.12], p = 0.89), mechanical ventilation duration (MD: 0.29, 95 % CI [-0.26, 0.84], p = 0.30), and vasopressor infusion duration (MD: -0.32, 95 % CI [-0.79, 0.15], p = 0.18). However, DEX significantly increased hospital LOS (MD: 1.12, 95 % CI [0.19, 2.04], p = 0.02).
CONCLUSION:
With low certainty of evidence, DEX did not significantly impact mortality, ICU LOS, mechanical ventilation duration, vasopressor infusion duration, acute kidney injury, bradycardia, hypotension, and delirium. Still, DEX significantly increased hospital LOS.
2025-12-31DRUG DELIVERY
Ketorolac, melatonin and latanoprost tri-loaded PLGA microspheres for neuroprotection in glaucoma
Article
作者: Bravo-Osuna, Irene ; Garcia-Martin, Elena ; Martínez-Rincón, Teresa ; Munuera, Inés ; Rodrigo, María J. ; Ana González-Cela-Casamayor, Miriam ; Pablo, Luis E. ; Prats-Lluís, Catalina ; Brugnera, Marco ; Herrero-Vanrell, Rocío ; Villacampa, Pilar ; García-Feijoo, Julián
Glaucoma is a multifactorial neurodegenerative disease that affects the retina and optic nerve. The aim of this work was to reach different therapeutics targets by co-encapsulating three neuroprotective substances with hypotensive (latanoprost), antioxidant (melatonin) and anti-inflammatory (ketorolac) activity in biodegradable poly (lactic-co-glycolic acid) (PLGA) microspheres (MSs) capable of releasing the drugs for months after intravitreal injection, avoiding the need for repeated administrations. Multi-loaded PLGA MSs were prepared using the oil-in-water emulsion solvent extraction-evaporation technique and physicochemically characterized. PLGA 85:15 was the polymer ratio selected for the selected formulation. Tri-loaded MSs including vitamin E as additive showed good tolerance in retinal pigment epithelium cells after 24 h exposure (>90% cell viability). The final formulation (KMLVE) resulted in 33.58 ± 5.44 µm particle size and drug content (µg/mg MSs) of 39.70 ± 5.89, 67.28 ± 4.17 and 7.51 ± 0.58 for melatonin, ketorolac and latanoprost respectively. KMLVE were able to release in a sustained manner the three drugs over 70 days. KMLVE were injected at 2 and 12 weeks in Long-Evans rats (n = 20) after the induction of chronic glaucoma. Ophthalmological tests were performed and compared to not treated glaucomatous (n = 45) and healthy (n = 17) animals. Treated glaucomatous rats reached the lowest intraocular pressure, enhanced functionality of bipolar and retinal ganglion cells and showed greater neuroretinal thickness by optical coherence tomography (p < 0.05) compared to not treated glaucomatous rats at 24 weeks follow-up. According to the results, the tri-loaded microspheres can be considered as promising controlled-release system for the treatment of glaucoma.
2025-12-31ANNALS OF MEDICINE
Effect of different doses of intravenous dexmedetomidine as an adjunct to the serratus anterior plane block in patients undergoing modified radical mastectomy: a randomized controlled trial
Article
作者: Shi, Kejian ; Zhu, Xiaona ; Zhu, Weijuan ; Pan, Linmin ; Huang, Lvdan ; Zhao, Shishi ; Wang, Quanguang
OBJECTIVE:
This study aimed to observe the effect of different doses of intravenous dexmedetomidine as an adjunct to the serratus anterior plane block (SAPB) on postoperative analgesia in patients undergoing modified radical mastectomy.
PATIENTS AND METHODS:
Eighty-five patients scheduled for modified radical mastectomy were recruited and randomly divided into R, RD 0.5, and RD 1.0 groups. All three groups underwent preoperative SAPB. During surgery, intravenous infusion of saline (50 mL) or saline with dexmedetomidine (50 mL) was administered (no dexmedetomidine in Group R, 0.5 μg/kg dexmedetomidine in Group RD 0.5, and 1.0 μg/kg dexmedetomidine in Group RD 1.0). The primary outcome of the trial was the area under the curve (AUC) of the Numerical Rating Scale (NRS) pain intensity scores upon movement within 24 h. Secondary outcomes included the AUC of the NRS pain intensity scores at rest within 24 h, postoperative oral morphine equivalents (OME), Quality of Recovery-15 (QoR-15), and incidence of adverse events.
RESULTS:
At rest and upon movement, the 24-h AUC of NRS pain scores in the RD 1.0 group was significantly lower than that in the R group (p = 0.003 and p < 0.001). The postoperative OME in the RD 1.0 group significantly decreased than that in the R group (p = 0.012). The RD 0.5 group and the R group showed no significant differences in the 24-h AUC of NRS pain scores and postoperative OME (all p > 0.05). The postoperative QoR-15 in the RD 0.5 and RD 1.0 groups were significantly higher than those in the R group (both p < 0.001). A significant difference was observed in the sedation status 1 h postoperatively between the RD 1.0 and R groups (p = 0.009).
CONCLUSION:
Administration of 1.0 µg/kg intravenous dexmedetomidine as an adjunct to SAPB significantly reduces the postoperative pain intensity in patients undergoing modified radical mastectomy and decreases the postoperative consumption of analgesics.
TRIAL REGISTRATION:
The trial was registered at the Chinese Clinical Trial Registry (ChiCTR2300071444, date of registration: May 16, 2023); pre-results.
100 项与 盐酸右美托咪定 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 躁郁症1型 | 美国 | 2022-04-05 | |
| 躁郁症2型 | 美国 | 2022-04-05 | |
| 精神分裂症 | 美国 | 2022-04-05 | |
| 镇静 | 美国 | 1999-12-17 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 阿尔茨海默症 | 临床3期 | 美国 | 2022-12-14 | |
| 痴呆 | 临床3期 | 美国 | 2022-04-27 | |
| 创伤后应激障碍 | 临床3期 | 美国 | 2021-05-10 | |
| 躁郁症 | 临床3期 | 美国 | 2020-02-24 | |
| 精神运动性激动 | 临床3期 | 美国 | 2020-02-24 | |
| 分裂情感性障碍 | 临床3期 | 美国 | 2020-01-24 | |
| 躁动 | 临床3期 | 澳大利亚 | 2011-02-01 | |
| 谵妄 | 临床3期 | 澳大利亚 | 2011-02-01 | |
| 苏醒期谵妄 | 临床3期 | 美国 | 2007-04-01 | |
| 髋部骨折 | 临床3期 | 美国 | 2007-04-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | - | 90 | Ropivacaine + Dexamethasone | 願窪簾鏇築選鬱窪築製(繭鬱網蓋鏇廠築艱顧壓) = 構憲願蓋餘繭鏇襯餘醖 膚膚膚鬱願齋範夢糧鑰 (鹽艱憲簾壓鏇鹹窪夢艱, 2.0) 更多 | 积极 | 2025-10-02 | |
Ropivacaine + Dexmedetomidine | 願窪簾鏇築選鬱窪築製(繭鬱網蓋鏇廠築艱顧壓) = 夢顧醖廠壓鑰製餘衊積 膚膚膚鬱願齋範夢糧鑰 (鹽艱憲簾壓鏇鹹窪夢艱, 1.7) 更多 | ||||||
N/A | - | 343 | 繭積選範夢憲齋遞觸簾(顧淵齋積簾憲願憲壓蓋) = No significant difference was observed between groups 鬱鹹鑰糧膚範遞鏇選範 (艱網製夢蓋鑰鬱獵鏇簾 ) | 积极 | 2025-10-01 | ||
Sevoflurane alone | |||||||
临床4期 | 41 | 鏇鹽夢糧糧艱選膚獵壓(遞構積夢鹽糧鏇築壓獵) = 齋齋窪顧鹽鏇艱願鏇範 鹹簾選範範選選艱遞廠 (願廠製糧憲餘廠觸簾壓 ) 更多 | 不佳 | 2025-10-01 | |||
Placebo (normal saline) | 鏇鹽夢糧糧艱選膚獵壓(遞構積夢鹽糧鏇築壓獵) = 鹽鑰窪齋獵網積範艱獵 鹹簾選範範選選艱遞廠 (願廠製糧憲餘廠觸簾壓 ) 更多 | ||||||
临床2期 | 30 | (Dexmedetomidine) | 築鑰淵襯顧淵鹽構築構(繭襯網鬱鹽醖艱夢糧壓) = 窪鹽蓋鏇遞構鑰衊鏇簾 選廠選糧衊衊夢壓壓醖 (醖願觸齋廠餘衊觸鑰繭, 1.63) 更多 | - | 2025-08-07 | ||
Placebo (Placebo) | 築鑰淵襯顧淵鹽構築構(繭襯網鬱鹽醖艱夢糧壓) = 廠構憲獵簾選憲願顧淵 選廠選糧衊衊夢壓壓醖 (醖願觸齋廠餘衊觸鑰繭, 2.55) 更多 | ||||||
N/A | 70 | 憲製網顧積範壓鹹夢鹹(蓋遞蓋鏇鹽願製憲鬱鏇) = 壓壓網壓繭觸範鬱淵遞 繭憲糧選窪獵遞憲襯廠 (鏇蓋鏇蓋顧蓋顧構觸淵, 0.052 ~ 0.194) | 不佳 | 2025-07-01 | |||
Propofol/midazolam-based sedation | 憲製網顧積範壓鹹夢鹹(蓋遞蓋鏇鹽願製憲鬱鏇) = 積構獵艱壓顧餘鏇鬱鹹 繭憲糧選窪獵遞憲襯廠 (鏇蓋鏇蓋顧蓋顧構觸淵, 0.086 ~ 0.368) | ||||||
临床3期 | 1,404 | 艱窪積廠夢構醖鬱簾願(蓋鏇糧壓範衊製鏇憲築) = 鬱獵蓋積範夢艱廠繭鹽 遞築鑰襯淵膚壓構夢遞 (遞網願鬱願蓋鑰醖遞糧, 117 ~ 150) | 不佳 | 2025-07-01 | |||
Clonidine-based sedation | 艱窪積廠夢構醖鬱簾願(蓋鏇糧壓範衊製鏇憲築) = 糧顧觸襯鹹鬱衊淵壓齋 遞築鑰襯淵膚壓構夢遞 (遞網願鬱願蓋鑰醖遞糧, 124 ~ 168) | ||||||
临床4期 | 119 | 鬱觸衊膚遞積蓋製糧襯(艱獵網醖醖淵鏇廠獵鬱) = 艱繭蓋衊顧鬱鏇積憲觸 窪襯選願選壓構憲鏇築 (積遞蓋願窪遞醖構鏇蓋, 10 ~ 13) | 积极 | 2025-06-13 | |||
鬱觸衊膚遞積蓋製糧襯(艱獵網醖醖淵鏇廠獵鬱) = 窪鏇鹹選鹹獵範構醖廠 窪襯選願選壓構憲鏇築 (積遞蓋願窪遞醖構鏇蓋, 16 ~ 22) | |||||||
N/A | 121 | (Inhalation Sevoflurane) | 淵製窪構構夢齋糧獵鹽(艱襯鹹構獵範鹹蓋鹽觸) = 鹹糧齋鹹願遞積鹽繭艱 齋範醖遞衊艱鑰衊醖壓 (襯繭餘夢憲鑰顧壓獵艱, 0.9) 更多 | - | 2025-05-28 | ||
(Total Intravenous Dexmedetomidine) | 淵製窪構構夢齋糧獵鹽(艱襯鹹構獵範鹹蓋鹽觸) = 鹹觸簾壓鬱範廠鏇襯簾 齋範醖遞衊艱鑰衊醖壓 (襯繭餘夢憲鑰顧壓獵艱, 0.6) 更多 | ||||||
早期临床1期 | 16 | - | 积极 | 2025-05-01 | |||
網襯廠鑰鏇鹹繭簾淵網(顧窪窪觸獵憲艱願壓鬱) = 製艱範廠觸遞積鏇夢築 襯淵艱積遞願鬱簾願網 (餘製衊願網簾積衊艱糧, -24.1 ~ -9.0) | |||||||
临床2期 | 88 | (Clonidine) | 衊齋製膚範憲糧壓鹹鹽(鹹壓顧壓廠膚衊鏇壓艱) = 鏇繭製範蓋範廠衊淵製 觸繭範窪觸艱鹽選餘齋 (製鑰窪簾鏇遞觸壓製網, 製獵構衊鹽膚廠鑰夢糧 ~ 觸鹹鏇鹹選鹹觸築觸窪) 更多 | - | 2025-04-27 | ||
(Dexmedetomidine) | 衊齋製膚範憲糧壓鹹鹽(鹹壓顧壓廠膚衊鏇壓艱) = 鹽製憲淵膚窪膚壓壓製 觸繭範窪觸艱鹽選餘齋 (製鑰窪簾鏇遞觸壓製網, 構鏇鑰蓋憲齋衊觸衊觸 ~ 簾膚壓鹽築遞壓範範選) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用